STStephanie E. Teng

Stephanie E. Teng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephanie E. Teng has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Abelchia: A Clinical Review of Retrograde Cricopharyngeus Dysfunction and Inability to Belch for Gastroenterologists

    by Chethan Ramprasad, C. Prakash Gyawali, Baha Moshiree, Adrianna Wierzbicka, Ofer Fass, Anthony Lembo, Vikram Rangan, Sarah Ballou, Trisha Pasricha, Stephanie E. Teng, et al.

    Abelchia, also termed the inability to belch syndrome, is an increasingly recognized upper esophageal sphincter (UES) disorder characterized by retrograde cricopharyngeal dysfunction (RCPD). This disorder is highly relevant to gastroenterologists since presentation consists of common upper gastrointestinal symptoms including chest pain, gurgling noises in the chest, abdominal pressure, and bloating, often misattributed to alternate foregut disorders. Abelchia is thought to result from absent or incomplete UES relaxation in response to retrograde esophageal air distension, causing esophageal air trapping, despite preserved anterograde swallowing-related UES relaxation. The diagnosis is suspected based on clinical presentation and absence of alternate esophageal structural/motor disorders and supported by high-resolution impedance manometry with carbonated beverage challenge. Injection of botulinum toxin into the UES during rigid esophagoscopy is the mainstay of treatment, though data supporting this are largely derived from case series. Symptom benefit typically outlasts the general duration of efficacy of botulinum toxin, suggesting retraining of retrograde UES relaxation and the ability to belch. Consequently, behavioral therapy has been also reported to be of benefit. Randomized trials, standardized diagnostic criteria, and long-term outcome studies are lacking. This review summarizes the evolving literature on abelchia with emphasis on clinical presentation, diagnostic evaluation, differential diagnosis, treatment, and the role of gastroenterologists in identifying this underrecognized disorder.

  • Response to Cricopharyngeal Dilation and Botulinum Toxin Injection Predicts Efficacy of Staged Myotomy in Cricopharyngeal Dysfunction

    by Lauren Schlegel, Sophie E. Yu, Annie R. Abruzzo, Brett Campbell, Stephanie Teng, Pavan S. Mallur

    Objectives: To date, no study has evaluated the use of cricopharyngeal (CP) dilation and botulinum toxin injection (BTX) as a temporary measure to predict myotomy outcomes. We hypothesize that symptom resolution following “trial” dilation and BTX predicts improvement following CP myotomy. Methods: Retrospective review of patients who underwent CP dilation and BTX followed by staged myotomy at a single institution. Pre- and postoperative EAT-10 scores for dilation and BTX and CP myotomy were used to calculate △EAT-10 scores. Univariate linear regression was performed to assess the association between dilation and BTX △EAT-10 and CP myotomy △EAT-10 scores. Results: Forty-two patients underwent CP dilation and BTX. Following CP dilation and Botox, patients who elected for no further treatment (n = 26) had a mean △EAT-10 was –2.93 (SD 8.810, P = .047), while patients who elected for later staged myotomy (n = 16) had a mean △EAT-10 of −5.85 (SD 6.923, P = .020) following dilation and BTX. Following CP myotomy, these 16 patients had mean △EAT-10 of −3.938 (SD 6.104, P = .021). Univariate linear regression revealed a positive association of △EAT-10 scores for dilation and BTX with CP myotomy △EAT-10 scores (β = .695, 95% CI = 0.384, 1.006, R 2 = .62, P < .001). Conclusion: CP dilation and BTX presents a low risk option to “trial” expected results of permanent and higher risk myotomy. Presence or absence of subjective improvement appears to track across both procedures and may help set patient expectations and optimize surgical candidate selection.

  • Valves for the Voiceless: Time to Speaking Valve Use in Posttracheostomy Patients After Multidisciplinary Initiative

    by Victoria W. Huang, Elliana K. DeVore, Sumedh Kaul, Mihir Parikh, Margaret M. Hayes, Stephanie E. Teng

    Objective: To review speaking valve (SV) use at a tertiary academic medical center and determine whether a multidisciplinary team implementation of SV protocols increased SV use and decreased time to SV trials.Methods: Retrospective case series of patients who underwent a tracheostomy between 2017 and 2023 before and after the dissemination of new protocols from a new multidisciplinary tracheostomy care initiative in 2019. The calendar days between meeting SV eligibility criteria and initial trial of SV were compared. Eligibility criteria for SV was defined as any patient ≥48 hours posttracheotomy who can breathe unassisted, off mechanical ventilation, tolerate a deflated cuff, and participate in an evaluation. Interrupted time series analysis using segmented negative binomial regression assessed the change in time to SV placement before and after protocol implementation.Results: A total of 421 patients were identified. After new protocols were disseminated, eligible patients with a SV trial increased from 75% to 95% with an increase in percentage of patients who tolerated the SV on their first attempt from 60% to 75%. Interrupted time series analysis demonstrated protocol implementation was associated with an overall 80% decrease in time to SV placement.Discussion: Continued barriers to SV implementation such as elevated tracheal pressures due to large tracheostomy sizes, or inappropriately early consultations with patients unable to participate in SV exam, may be amenable to further institution‐level quality improvement initiatives.Implications for Practice: A multidisciplinary initiative's dissemination of protocols with algorithms for SLP consultation and SV use can help standardize post‐operative tracheostomy care.

  • Airway Management in Singers: A Cross-sectional Survey

    by Stephanie E. Teng, Jacqueline R. Booth, Mark A. Fritz, Michael W. Groves, Gregory N. Postma


  • Open Access

    Abstract 3190: Investigating tumor-mesothelial cell interactions during ovarian cancer metastasis

    by Angela Schab, Elena Lomonosova, Isaac Cooper, Stephanie Teng, Zainab Ibitoye, Danny Wilke, Hollie Noia, Maggie Mullen, Gregory Longmore, Katherine Fuh

    Introduction: Ovarian cancer is the leading cause of gynecological cancer-related deaths. The propensity for metastasis is a driving factor for the poor outcomes associated with this disease, but there is currently no effective therapy targeting metastasis. Work from our lab has demonstrated that stromal cell expression of the receptor tyrosine kinase Discoidin Domain Receptor 2 (DDR2) promotes ovarian cancer metastasis. One stromal compartment that expresses DDR2 is the mesothelial cell layer that surrounds the organs of the peritoneum - the most common location of ovarian cancer metastasis. Although epithelial in origin, mesothelial cells can adopt mesenchymal properties during metastasis and become active participants in the process. Therefore, we hypothesize that mesothelial cell expression of DDR2 promotes stabilization of a mesenchymal phenotype in mesothelial cells, which facilitates ovarian cancer metastasis. Methods: Human peritoneal mesothelial cells (HPMCs) were isolated from patient omentum samples. HPMCs were immortalized using lentivirus expressing SV40 large T antigen followed by short hairpin control and DDR2 knockdown transfections. qPCR was used to assess transcription and immunoblotting was used to assess protein expression. ELISAs were completed to observe changes in MMP-2 secretion. C57BL6/J mice are used for in vivo studies. Results: In vitro we have found that DDR2-expressing human peritoneal mesothelial cells promote tumor cell clearance through the mesothelial cell layer. Further, mesothelial cell DDR2 increases mesenchymal-associated gene transcription and signaling, including the mesenchymal associated transcription factor SNAI1 and collagen 1. Mesothelial cell DDR2 expression also leads to increased secretion of the protease MMP-2, which is known to promote metastasis. To determine whether mesothelial cell DDR2 expression contributes to metastasis, we are creating a mesothelial cell-specific DDR2 knockout mouse and control mouse. To do so, we are breeding WT1CreERT2/+ mice as a mesothelial cell specific driver of Cre recombination with DDR2 floxed mice to knockout DDR2 as a result of Cre recombination, and Ai14 mice as a Cre reporter as they express tdTomato only in the presence of Cre. After validation of the model, syngeneic ovarian cancer cells will be intraperitoneally injected and tumor burden, ECM structure, and signaling changes will be compared between knockout and control mice. Conclusions: This work will increase our understanding of mesothelial cells’ contribution to metastasis with the possibility of identifying inhibition of DDR2 as a therapeutic target for ovarian cancer patients. Citation Format: Angela Schab, Elena Lomonosova, Isaac Cooper, Stephanie Teng, Zainab Ibitoye, Danny Wilke, Hollie Noia, Maggie Mullen, Gregory Longmore, Katherine Fuh. Investigating tumor-mesothelial cell interactions during ovarian cancer metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3190.